Avidity Biosciences, a San Diego-based company, announced a partnership with Eli Lilly and is also facing acquisition interest from Novartis.
7 reports, 6 independent
Updated Sep 11
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 7
- Developments
- 7
- Repetition
- 14%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Avidity Biosciences, a San Diego-based company, announced a partnership with Eli Lilly and is also facing acquisition interest from Novartis.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Sub-event
Novartis is actively pursuing Avidity Biosciences in an acquisition attempt.1 source
Novartis completed the acquisition of Avidity for $12 billion.1 source
Avidity and Novartis are involved in a major corporate action following acquisition interest.1 source
Novartis completed the acquisition of Avidity Biosciences, which was previously under acquisition interest.1 source
Avidity partners with Eli Lilly and is targeted for acquisition by Novartis.1 source
FDA granted Breakthrough Therapy designation to Avidity's DMD drug as Novartis pursues acquisition.1 source
Keep exploring
The entities involved
-
Avidity
American biotech company
Nothing else this week.
-
Novartis
Swiss-American multinational pharmaceutical corporation
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Novartis acquired Regulus Therapeutics in April, while also reportedly weighing a potential deal with Avidity Biosciences.
- Partnership expands Novartis's oncology pipeline.
- Novartis sought Swissmedic regulatory approval for a drug, which was co-funded by Sida and introduced first in Ghana.
- Eli Lilly announced multiple new partnerships, including expanding Zepbound access with CVS Health, collaborating with Insilico Medicine, and investing in an AI lab with NVIDIA.
- Novartis is offering potential support to the national health fund in Ghana, which provides equipment and support to the Komfo Anokye Teaching Hospital.
Coverage
Newest first; wire copies grouped- yahoo.com
- 933thedrive.com
- yahoo.com
- morningstar.com
- ZacksRNA Stock Moves More Than 30% in a Week: What's Driving This Rally? Shares of Avidity Biosciences RNA have soared 36% in the past month, all thanks to a report issued by the Financial Times (FT), whi
- Investing.comAvidity Biosciences stock soars on Novartis takeover approach report Investing.com -- Avidity Biosciences (NASDAQ:RNA) stock surged 18% Wednesday after the Financial Times reported that Swiss pharmac
- Insider MonkeyAvidity (RNA) Gets 26% Jump on Potential Takeover We recently published 10 Stocks With Easy 15-30% Upside. Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the best-performing stocks on Wednesday. Av